TY  - JOUR
T1  - Development and Validation of Novel Clinicopathological Risk Models for Mantle Cell Lymphoma in the Era of Modern Immunochemotherapy
A1  - Nguyen Thanh Huy
A1  - Pham Quang Minh
A1  - Le Thi Bich
A1  - Tran Van Nam
JF  - Archive of International Journal of Cancer and Allied Science
JO  - Arch Int J Cancer Allied Sci
SN  - 3108-4834
Y1  - 2026
VL  - 6
IS  - 1
DO  - 10.51847/yhEt19Bajq
SP  - 289
EP  - 300
N2  - Individuals diagnosed with mantle cell lymphoma (MCL) demonstrate substantial diversity in both their clinical manifestations and long-term prognosis. Nevertheless, the prognostic tools currently in widespread use are outdated and fail to meet the requirements of modern multidisciplinary care for this malignancy. The current investigation aims to characterize the clinical and pathological features of MCL in the context of immunochemotherapy and to develop enhanced prognostic tools that more reliably predict patient outcomes. The North American Mantle Cell Lymphoma Project constitutes a collaborative effort across 23 institutions in North America dedicated to assessing and optimizing prognostic factors for initial treatment. This analysis encompasses 586 cases of MCL diagnosed from 2000 to 2012. An extensive retrospective review examined clinicopathological characteristics, therapeutic interventions, and survival endpoints. Novel prognostic models were formulated following detailed evaluation of pretreatment variables and were subsequently tested for validity in a separate, independent group of MCL patients. In frontline treatment regimens, hematopoietic stem cell transplantation was the predominant determinant of clinical endpoints, exerting highly significant effects on both overall survival (OS, P 
UR  - https://smerpub.com/article/development-and-validation-of-novel-clinicopathological-risk-models-for-mantle-cell-lymphoma-in-the-emdtvsgpe4yinup
ER  -